Literature DB >> 19809406

Increased prevalence of and associated mortality with methicillin-resistant Staphylococcus aureus among hospitalized IBD patients.

Geoffrey C Nguyen1, Harshna Patel, Rachel Y Chong.   

Abstract

OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) infection has become increasingly prevalent in US hospitals, and the impact of MRSA on hospitalized inflammatory bowel disease (IBD) patients is unknown.
METHODS: We used the Nationwide Inpatient Sample to identify admissions for IBD (n=116,842) between 1998 and 2004. We compared prevalence and in-hospital mortality of MRSA among IBD, non-IBD gastrointestinal (GI), and general medical inpatients.
RESULTS: MRSA prevalence increased from 4.5/10,000 to 19.0/10,000 over the 7-year period (P<0.0001). After adjustment for confounders, IBD inpatients were at increased risk of MRSA compared with the non-IBD GI (adjusted odds ratio (aOR) 1.61; 95% confidence interval (CI): 1.33-1.96) and general medical (aOR 1.36; 95% CI: 1.11-1.66) groups. Of those with MRSA, catheter-related infections were specifically more common among IBD compared with non-IBD GI and general inpatients (28.8% vs. 11.0% and 8.5%, respectively, P<0.0002). Bowel surgery, parenteral nutrition, and health insurance were predictors of MRSA infection, but the first two became insignificant after controlling for length of stay (LOS). Compared with LOS < or = 7 days, MRSA was more likely among those hospitalized 8-21 days (aOR 7.40; 95% CI: 4.68-11.7) and >21 days (aOR 58.6; 95% CI: 36.0-95.3). MRSA infection was associated with sevenfold increase in mortality (aOR 7.61; 95% CI: 3.33-17.4).
CONCLUSIONS: Hospitalized IBD patients are at increased risk of MRSA compared with non-IBD GI and general medical inpatients. Increased mortality in the IBD population associated with MRSA reinforces the importance of measures to prevent nosocomial infection and to reduce length of hospitalization.

Entities:  

Mesh:

Year:  2009        PMID: 19809406     DOI: 10.1038/ajg.2009.581

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

Review 1.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

Review 2.  Gut Microbiota and Celiac Disease.

Authors:  Giovanni Marasco; Anna Rita Di Biase; Ramona Schiumerini; Leonardo Henry Eusebi; Lorenzo Iughetti; Federico Ravaioli; Eleonora Scaioli; Antonio Colecchia; Davide Festi
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

3.  Crohn's disease complicated by intestinal infection with methicillin-resistant Staphylococcus aureus.

Authors:  Dominik Bettenworth; Tobias M Nowacki; Alexander Friedrich; Karsten Becker; Johannes Wessling; Jan Heidemann
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

4.  Antimicrobial photodynamic therapy in the colon: delivering a light punch to the guts?

Authors:  Mark Wainwright; Tianhong Dai; Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2011-04-12       Impact factor: 3.421

5.  Prevalence and incidence of antimicrobial-resistant organisms among hospitalized inflammatory bowel disease patients.

Authors:  Alon Vaisman; Kevin Pivovarov; Allison McGeer; Barbara Willey; Bjug Borgundvaag; Vanessa Porter; Piraveina Gnanasuntharam; Yanliang Wei; Geoffrey C Nguyen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Altered Pattern of Immunoglobulin A-Targeted Microbiota in Inflammatory Bowel Disease After Fecal Transplantation.

Authors:  Wen-Qi Huang; Hong-Li Huang; Wu Peng; Yan-Di Liu; You-Lian Zhou; Hao-Ming Xu; Liang-Jie Zhang; Chong Zhao; Yu-Qiang Nie
Journal:  Front Microbiol       Date:  2022-06-22       Impact factor: 6.064

7.  Detecting Microbial Dysbiosis Associated with Pediatric Crohn Disease Despite the High Variability of the Gut Microbiota.

Authors:  Feng Wang; Jess L Kaplan; Benjamin D Gold; Manoj K Bhasin; Naomi L Ward; Richard Kellermayer; Barbara S Kirschner; Melvin B Heyman; Scot E Dowd; Stephen B Cox; Haluk Dogan; Blaire Steven; George D Ferry; Stanley A Cohen; Robert N Baldassano; Christopher J Moran; Elizabeth A Garnett; Lauren Drake; Hasan H Otu; Leonid A Mirny; Towia A Libermann; Harland S Winter; Kirill S Korolev
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

8.  Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study.

Authors:  Idan Goren; Adi Brom; Henit Yanai; Amir Dagan; Gad Segal; Ariel Israel
Journal:  United European Gastroenterol J       Date:  2019-09-05       Impact factor: 4.623

9.  13-year mortality trends among hospitalized patients with inflammatory bowel disease.

Authors:  Justin L Sewell; Hal F Yee
Journal:  BMC Gastroenterol       Date:  2012-06-26       Impact factor: 3.067

Review 10.  Inflammatory bowel disease cause-specific mortality: a primer for clinicians.

Authors:  Zain Kassam; Sara Belga; Idan Roifman; Simon Hirota; Humberto Jijon; Gilaad G Kaplan; Subrata Ghosh; Paul L Beck
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.